De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

EBOS Group Inkomsten in het verleden

Verleden criteriumcontroles 3/6

EBOS Group is de winst gegroeid met een gemiddeld jaarlijks percentage van 13.5%, terwijl de Healthcare industrie de winst daalde met 3.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 12.1% per jaar. Het rendement op eigen vermogen van EBOS Group is 11.3%, en het heeft een nettomarge van 2.1%.

Belangrijke informatie

13.5%

Groei van de winst

8.4%

Groei van de winst per aandeel

Healthcare Groei van de industrie	2.4%
Inkomstengroei	12.1%
Rendement op eigen vermogen	11.3%
Nettomarge	2.1%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe EBOS Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

ASX:EBO Opbrengsten, kosten en inkomsten (AUD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	13,189	272	567
31 Mar 24	12,932	264	557
31 Dec 23	12,674	257	547
30 Sep 23	12,456	255	540
30 Jun 23	12,237	253	532
31 Mar 23	11,933	243	509
31 Dec 22	11,629	233	485
30 Sep 22	11,182	218	454
30 Jun 22	10,734	203	423
31 Mar 22	10,267	198	403
31 Dec 21	9,800	194	384
30 Sep 21	9,502	190	370
30 Jun 21	9,203	185	357
31 Mar 21	9,123	180	350
31 Dec 20	9,043	174	344
30 Sep 20	8,904	168	335
30 Jun 20	8,766	163	326
31 Mar 20	8,288	157	328
31 Dec 19	7,810	152	330
30 Sep 19	7,370	145	336
30 Jun 19	6,930	138	341
31 Mar 19	6,909	136	338
31 Dec 18	6,888	134	334
30 Sep 18	6,937	136	331
30 Jun 18	6,987	137	329
31 Mar 18	7,016	134	320
31 Dec 17	6,927	129	306
30 Sep 17	6,998	126	292
30 Jun 17	7,271	127	285
31 Mar 17	7,023	122	266
31 Dec 16	7,396	127	270
30 Sep 16	7,033	123	260
30 Jun 16	6,797	122	255
31 Mar 16	6,057	110	232
31 Dec 15	5,957	109	233
30 Sep 15	5,641	101	221
30 Jun 15	5,343	93	211
31 Mar 15	5,868	100	233
31 Dec 14	5,608	92	225
30 Sep 14	5,182	84	209
30 Jun 14	5,345	85	217
31 Mar 14	4,598	72	187
31 Dec 13	3,746	58	153

Kwaliteitswinsten: EBO heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (2.1%) EBO } zijn lager dan vorig jaar (2.1%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van EBO is de afgelopen 5 jaar met 13.5% per jaar gegroeid.

Versnelling van de groei: De winstgroei van EBO over het afgelopen jaar ( 7.2% ) ligt onder het 5-jarig gemiddelde ( 13.5% per jaar).

Winst versus industrie: De winstgroei EBO over het afgelopen jaar ( 7.2% ) overtrof de Healthcare -sector -25.4%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 11.3% ) van EBO wordt als laag beschouwd.

EBOS Group Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First half 2024 earnings released: EPS: AU$0.71 (vs AU$0.70 in 1H 2023)

EBOS Group Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

EBOS Group Limited to Report First Half, 2024 Results on Feb 21, 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Final dividend of NZ$0.64 announced

EBOS Group Limited Announces Final Dividend, Payable on 18 September 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Chief Financial Officer Changes

Insider recently sold AU$4.9m worth of stock

First half dividend of NZ$0.60 announced

First half 2024 earnings released: EPS: AU$0.71 (vs AU$0.70 in 1H 2023)

EBOS Group Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Now 20% undervalued

EBOS Group Limited to Report First Half, 2024 Results on Feb 21, 2024

EBOS Group Limited (NZSE:EBO) acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million.

Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk

EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit

EBOS Not to Proceed with Acquisition in Animal Care Segment

EBOS Not to Proceed with Acquisition in Animal Care Segment

Now 21% undervalued

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended June 30, 2023, Payable on 29 September, 2023

Now 21% undervalued

Upcoming dividend of NZ$0.60 per share at 3.0% yield

Ebos Group Limited Announces Dividend, Payable on 29 September 2023

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorates as stock falls 17%

Now 26% undervalued after recent price drop

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited to Report Q2, 2023 Results on Feb 22, 2023

EBOS Group Limited Announces the Appointment of Mark Bloom as an Independent Director, Effective 16 September 2022

Upcoming dividend of NZ$0.51 per share

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Dividend for the Six Months Ended June 30, 2022, Payable on 30 September, 2022

Upcoming dividend of NZ$0.49 per share

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended December 31, 2021, Payable on March 18, 2022

Ebos Group Limited Announces Resignation of Nick Dowling as Director

Independent Director recently bought AU$55k worth of stock

Price target increased to AU$31.66

EBOS Group Limited Announces Supplementary Dividend for the Six Months Ended June 30, 2021, Payable on Sept. 24, 2021

Upcoming dividend of NZ$0.48 per share

EBOS Group Limited (EBOS) acquired Sentry Medical.

Full year 2021 earnings released: EPS AU$1.13 (vs AU$1.01 in FY 2020)

EBOS Group Limited (NZSE:EBO) acquired Pioneer Medical Limited for AUD 40 million.

Price target raised to AU$25.70

First half 2021 earnings released: EPS AU$0.57 (vs AU$0.51 in 1H 2020)

Revenue beats expectations

EBOS Group Limited (NZSE:EBO) acquired Vet Distribution Business of Clifford Hallam Healthcare Pty Ltd for AUD 9.2 million.

EBOS Group Limited (NZSE:EBO) acquired CH2 Vet for AUD 9.2 million.

EBOS Group Limited, Annual General Meeting, Oct 19, 2021

New 90-day high: AU$27.92

New 90-day high: AU$25.25

EBOS Group Limited (NZSE:EBO) entered into an agreement to acquire Cryomed Aesthetics Pty Limited for AUD 14.1 million.

New 90-day high: AU$23.26

New 90-day high - AU$21.38

Full year earnings released - EPS AU$1.01

New 90-day low - AU$20.00

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden